In a significant advancement for perioperative care and neuro-monitoring, Masimo, a subsidiary of the Danaher Corporation, has announced that its innovative smartSedLine brain function monitor has been granted the CE mark. This regulatory milestone clears the path for the device’s commercial rollout across applicable European markets, promising to redefine how clinicians track patient sedation levels and manage anaesthetic depth with unprecedented precision.
By leveraging sophisticated artificial intelligence (AI) to process bilateral frontal electroencephalogram (EEG) signals, the smartSedLine system represents a generational leap over traditional monitoring tools. As hospitals across Europe strive to reduce the risks associated with general anaesthesia, this technology offers a vital, data-driven approach to individualizing patient care.
The Core Innovation: Elevating Anaesthetic Management
At the heart of the smartSedLine system is a next-generation AI-powered Patient State Index (PSi) algorithm. Anaesthesia is an inherently complex physiological state, and ensuring that a patient remains appropriately sedated—neither too light, which risks awareness, nor too deep, which can lead to postoperative complications—is a primary challenge for anaesthesiologists.
The smartSedLine monitor addresses this by continuously processing and displaying four real-time bilateral frontal EEG waveforms. The system translates these complex electrical signals into a clear, numerical index ranging from 0 to 100. This PSi provides clinicians with an at-a-glance assessment of a patient’s sedation level.
What distinguishes the smartSedLine from its predecessors is its enhanced responsiveness. During the critical induction phase of anaesthesia, brain activity shifts rapidly. The new algorithm is specifically engineered to detect these shifts with greater sensitivity, allowing clinicians to titrate anaesthetic agents more accurately. Furthermore, the system demonstrates superior stability when EEG power is low—a phenomenon frequently encountered in geriatric populations and critically ill patients, where traditional monitors often struggle to provide consistent, reliable data.
Chronology: The Path to European Approval
The journey of the smartSedLine monitor is part of a broader narrative of innovation and strategic corporate realignment within the medical technology sector.
- Mid-2020s (Developmental Phase): Masimo invested heavily in deep-learning algorithms, focusing on the processing of EEG data in low-signal environments to assist in neuro-monitoring.
- February 2026: In a move that signaled a massive shift in the diagnostics and telehealth landscape, the Danaher Corporation reached a definitive agreement to acquire Masimo in an all-cash transaction valued at $9.9 billion. This acquisition was designed to integrate Masimo’s world-class monitoring portfolio into Danaher’s expansive diagnostics and life sciences ecosystem.
- August 2026: Following the finalization of the integration process, Masimo announced the receipt of the CE mark for the smartSedLine monitor. This regulatory approval serves as a testament to the safety and efficacy of the device under the stringent requirements of the European Medical Device Regulation (MDR).
- Current Status: The device is now transitioning into European clinical settings. Meanwhile, in the United States, the smartSedLine PSi remains 510(k) pending, as the company continues to work with the FDA to bring this technology to the American market.
Supporting Data: Why Stability and Sensitivity Matter
The clinical utility of the smartSedLine lies in its ability to solve the "noise vs. signal" dilemma that has long plagued EEG monitoring in the operating room.
1. The Challenge of Geriatric and Critically Ill Patients
Geriatric patients often exhibit lower baseline EEG power, which can lead to "flat" or erratic readings on legacy monitors. This lack of data can cause clinicians to inadvertently overdose patients on anaesthetic drugs. By maintaining stability in low-power environments, the smartSedLine ensures that the PSi remains a reliable indicator, reducing the risk of postoperative delirium and cognitive decline, which are significant concerns in elderly patient cohorts.
2. Improved Induction Responsiveness
Induction is the "high-stakes" period of surgery. The speed at which a patient transitions from wakefulness to unconsciousness requires real-time, high-fidelity monitoring. The smartSedLine’s AI-powered algorithm provides a faster, more accurate reflection of these transitions, effectively closing the "latency gap" that existed in older monitoring systems.
3. Individualized Care
By providing more granular data, the monitor supports "precision anaesthesia." Instead of relying on weight-based or age-based standard dosing, clinicians can observe the direct physiological response of the patient’s brain, adjusting drug delivery in real-time to match the patient’s specific neurological state.
Official Responses: Insights from Clinical Leadership
The introduction of the smartSedLine has been met with optimism from clinical leaders who emphasize the necessity of reliable data in high-pressure medical environments.
Dr. Basil Matta, Chief Medical Officer at Masimo, highlighted the significance of the technology in a recent statement: "The brain can change rapidly under anaesthesia, and clinicians need information that responds to those changes while remaining reliable in challenging conditions."
Dr. Matta further explained the impact of the AI integration: "With smartSedLine, we are applying advanced AI techniques to brain function monitoring to deliver a more responsive Patient State Index that better reflects underlying brain activity. By improving responsiveness during induction and stability under low EEG power, we can provide clinicians with meaningful insights to help individualise anaesthetic management for each patient."
This sentiment reflects the industry’s broader movement toward "intelligent" monitors—devices that do not merely display raw data but interpret it, offering clinical decision support that helps reduce the cognitive load on healthcare providers.
Broader Implications for Healthcare
The CE mark for smartSedLine has far-reaching implications for both the medical device industry and patient outcomes.
Impact on Clinical Workflow
For hospitals, the adoption of smartSedLine potentially reduces the time spent on manual adjustments of anaesthetic titration. By providing a clear, evidence-based index, it assists in standardizing the quality of care across different surgical departments. This is particularly relevant in high-volume hospitals where junior anaesthesiologists may rely on standardized protocols that can be further optimized by real-time EEG feedback.
The Danaher-Masimo Synergy
The acquisition of Masimo by Danaher is clearly bearing fruit. By integrating Masimo’s signal-processing prowess with Danaher’s distribution and diagnostics capabilities, the smartSedLine is poised for a more rapid adoption curve than if it had remained independent. This partnership highlights the trend of consolidation, where large conglomerates acquire niche, high-tech innovators to dominate the "connected hospital" space.
Future Outlook
As the smartSedLine begins to permeate European operating theatres, its performance data will likely fuel further research into the correlation between intraoperative EEG stability and long-term surgical outcomes. Furthermore, the pending 510(k) application in the US suggests that Masimo is preparing for a global launch.
If the technology proves as effective in clinical practice as it has in controlled testing, it may soon become a standard of care. The ultimate goal—reducing the incidence of intraoperative awareness and minimizing the dosage of anaesthetics—is a win for patients, providers, and healthcare systems seeking to improve efficiency and safety simultaneously.
In conclusion, the approval of the smartSedLine monitor is more than just a regulatory win for Masimo. It represents a significant step toward a future where the operating room is an environment of profound clinical precision, powered by artificial intelligence and designed to protect the most vulnerable organ in the human body: the brain. As European clinicians begin to integrate this technology into their daily practice, the global medical community will be watching closely to quantify the benefits of this AI-driven evolution in anaesthesia.
About the Author
